Stefanatou Maria, Vasileiadou Kapetanou Eirini, Kimiskidis Vasilios K, Papaliagkas Vasileios, Polychronopoulos Panagiotis, Markoula Sofia, Charisiou Kleoniki, Kazis Dimitrios, Verentzioti Anastasia, Patrikelis Panayiotis, Alexoudi Athanasia, Gatzonis Stylianos
1st Department of Neurology, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Department of Applied Statistics, University of Piraeus, 185 34 Piraeus, Greece.
Pharmaceuticals (Basel). 2021 Feb 19;14(2):165. doi: 10.3390/ph14020165.
Brivaracetam (BRV) is the latest approved antiepileptic drug. The aim of the study was to evaluate the efficacy and tolerability of BRV in everyday clinical practice. In this retrospective, observational, multicenter study, data from epilepsy patients receiving BRV from January 2018 to July 2019 were analyzed. Patients with age ≥16 suffering from any type of epilepsy and having at least one follow up encounter after dose titration were included. 156 consecutive patients were included in the study. The mean age was 40 (16-84 years) and the mean duration of epilepsy was 21 years. Of the 156 patients, 81% were diagnosed with focal-onset seizures, 16% with generalized seizures, while 3% suffered from unclassified seizures. Nine patients received BRV as monotherapy as a switching therapy. At the first follow up visit, seizure cessation was achieved in 56 (36%) patients and the rate of ≥50% responders was 36%. Twenty four patients (15%) remained unchanged; six patients (4%) were recorded with increased seizure frequency, while the remaining 9% had a response of less than 50% Twenty-six patients (17%) showed clinically significant adverse events, but none were life threatening. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in the clinical setting.
布瓦西坦（BRV）是最新获批的抗癫痫药物。本研究旨在评估布瓦西坦在日常临床实践中的疗效和耐受性。在这项回顾性、观察性、多中心研究中，分析了2018年1月至2019年7月接受布瓦西坦治疗的癫痫患者的数据。纳入年龄≥16岁、患有任何类型癫痫且在剂量滴定后至少有一次随访的患者。156例连续患者纳入研究。平均年龄为40岁（16 - 84岁），癫痫平均病程为21年。156例患者中，81%被诊断为局灶性发作，16%为全身性发作，3%为未分类发作。9例患者接受布瓦西坦作为转换治疗的单药治疗。在首次随访时，56例（36%）患者实现了癫痫发作停止，≥50%反应者的比例为36%。24例患者（15%）病情无变化；6例患者（4%）癫痫发作频率增加，其余9%的患者反应小于50%。26例患者（17%）出现临床显著不良事件，但均无生命危险。在临床环境中，布瓦西坦似乎是一种有效、易用且安全的抗癫痫药物。
